Cite Filings / PRLD / 0000950170-23-025712

Feed Companies Filings Check

Sign in

8-K

Current Report

Prelude Therapeutics Inc Filed 2023-06-01 Acc 0000950170-23-025712

Regulation FD disclosure

Item 7.01 Regulation FD disclosure

From the SEC's structured data for this filing

Documents 1

8-K Current Report , prld-20230601.htm

Around this filing

2023-06-21 8-K Shareholder vote results
2023-06-01 8-K Regulation FD disclosure
2023-05-26 4 CEO bought 1,900 shares at an average $5.15 ($9,790)
2023-05-25 4 Chief Legal Officer, Corp Sec. bought 2,400 shares at $5.39 ($12,936)
2023-05-25 4 Chief Financial Officer bought 5,000 shares at $5.50 ($27,500)
2023-05-25 4 CEO bought 11,856 shares at $5.63 ($66,749)
2023-05-19 8-K Material agreement · Other events

Link to a passage

Paste a passage to link it

At least 12 characters, not counting spaces, so the link points to one passage.

External

SEC EDGAR (opens in new tab)
SEC Structured Data (opens in new tab)

Loading prld-20230601.htm…

Connection lost

Reconnecting…

Cite Filings isn't responding

Reconnecting…